Medicine Recommendations

Various indications - see Palliative Care Clinical Practice Summary Guidance

Pagets Disease

Pain

Pain

Dietary management of patients with cystic fibrosis

Pain

Depressive illness, post-traumatic stress disorder, obsessive compulsive disorder, panic disorder, social phobia, generalised anxiety disorder

For treating hyperkalaemia (TA 623)

Age-related macular degeneration (NICE TA155)

NICE TA 155 - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration

All indications

Rheumatic diseases

​​

Pentosan Polysulfate Sodium for treating bladder pain (NICE TA610)

Peripheral arterial disease (NICE TA223)

NICE TA223 - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease 

Partial-onset seizures with or without secondary generalised seizures

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products   

Schizophrenia and other psychoses, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour

Heart failure, hypertension, diabetic nephropathy and prophylaxis of cardiovascular events

Schizophrenia and other psychoses, mania, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

injection 200mg / ml

Third line for patients who fail to respond to combined use of midazolam and anti psychotic (usually levomepromazine) for refractory agitation at the end of life.

Hypertensive episodes in phaeochromocytoma